ABSTRACT
Los antibióticos y analgésicos han sido descritos frecuentemente como las principales causas de toxicidad hepática. Los esteroides anabólicos se han relacionado también con alteraciones en sistemas como el cardiovascular o el hepático; en este último causan colestasis, carcinoma hepatocelular, hiperplasia regenerativa nodular y sangrado de varices, secundario a hipertensión portal. Es importante entonces considerar los esteroides anabólicos como factores de riesgo para hepatotoxicidad. Se presenta el primer caso en Colombia y uno de los pocos en Latinoamérica, de colestasis asociada únicamente al uso de estanozolol. Se trata de un paciente de 21 años, en tratamiento con el medicamento para incrementar la masa muscular, que presentó compromiso hepático de tipo colestásico. Se descartaron otras posibles causas de ictericia, mediante la escala CIOMS/RUCAM se llegó a establecer causalidad entre el consumo de estanozolol y la colestasis. El objetivo de este reporte es hacer una descripción no reportada en la literatura colombiana y poco común en la literatura mundial.
Antibiotics and pain relievers have been frequently described as the main causes of liver toxicity. Anabolic steroids have also been linked to alterations in systems such as cardio-vascular or liver. In the latter, they seem to cause cholestasis, hepatocellular carcinoma, nodular regenerative hyperplasia and variceal bleeding secondary to portal hypertension. It is important to consider them as factors associated with hepatotoxicity. The first case in Colombia and one of the few in Latin America of cholestasis associated only to the use of Stanozolol is presented in a 21-year-old patient under treatment with the drug to increase muscle mass. The patient presented with cholestatic liver involvement. Other possible causes of jaundice were ruled out. From the CIOMS / RUCAM scale, causality was established between the consumption of Stanozolol and cholestasis. The objective of this case is to report a case not found in Colombian literature and little reported in world literature.
Antibióticos e analgésicos têm sido frequentemente descritos como as principais causas de toxicidade hepática. Os esteroides anabolizantes também têm sido relacionados a alterações em sistemas como cardiovasculares ou hepáticos; neste último, causam colestase, carcinoma hepatocelular, hiperplasia nodular regenerativa e sangramento varicoso, secundário à hipertensão portal. Portanto, é importante considerar os este-roides anabolizantes como fatores de risco para hepatotoxicidade. O primeiro caso é apresentado na Colômbia e um dos poucos na América Latina, de colestase associada apenas ao uso de estanozolol. Paciente de 21 anos, em tratamento com fármaco para aumento de massa muscular, apresentou acometimento hepático colestático. Outras possíveis causas de icterícia foram descartadas, a escala CIOMS / RUCAM estabeleceu causalidade entre o consumo de estanozolol e colestase. O objetivo deste relatório é fazer uma descrição não relatada na literatura colombiana e rara na literatura mundial
Subject(s)
Humans , Stanozolol , Anabolic Agents , Cholestasis , Testosterone Congeners , Jaundice , LiverABSTRACT
Abstract Background: The use of androgenic anabolic steroids (AAS) is prevalent among young bodybuilders, motivated by aesthetic results. Although the medical community condemns this practice for its potential deleterious effect, we must recognize the need for more scientific research on the likelihood and magnitude of the adverse events. Objective: To evaluate whether high-quality, scientific evidence supports that AAS negatively affect lipid profile and promote muscle hypertrophy in resistance training practitioners. Methods: A systematic review of the literature of randomized clinical trials was conducted in the PubMed / Medline, Scielo and Science direct databases. The searches were conducted by two independent researchers by June 2018. A significance level of 5% was considered in the analysis. Results: Six clinical trials involving 170 resistance training practitioners were included. A significant heterogeneity was found in studies evaluating the effects of AAS on lipid profile and muscle hypertrophy (I² = 97, 95 and 91%, respectively), with no significant effects on HDL-cholesterol (-5.62mg/dL, 95%CI −12.10, 0.86, p= 0.09), LDL-cholesterol (7.76 mg/dL, 95%CI −9.70, 25.23, p= 0.57) and muscle hypertrophy (2.44kg 95%CI 0.02, 4.86, p=0.05). Conclusion: Current evidence does not support that low-to-moderate doses of AAS cause serious negative effects on lipid profile or promote muscle hypertrophy in resistance training practitioners.
Subject(s)
Receptors, Androgen , Cholesterol/blood , Testosterone Congeners/pharmacology , Resistance Training , Skeletal Muscle Enlargement/drug effects , Testosterone Congeners/adverse effects , LipidsABSTRACT
Abstract Anabolic substances have been increasingly used by bodybuilders and athletes with the goal of improving performance and aesthetics. However, this practice has caused some concern to physicians and researchers because of unknowledge of consequences that the indiscriminate and illicit use of these substances can cause. Thus, this study analyzed the effects of two commercially available anabolic steroids (AS), Winstrol Depot® (Stanozolol) and Deposteron® (Testosterone Cypionate), in the neuronal density of limbic, motor and sensory regions on the cerebral cortex and in CA1, CA2, CA3 regions of the hippocampus. A total of 60 Swiss mice were used (30 males and 30 females), separated into three groups: control and two experimental groups, which received the AAS. From each brain, homotypic and semi-serial samples were taken in frontal sections from areas established for the study. The results showed that females treated with testosterone cypionate presented a reduction in all regions tested and the ones treated with Stanozolol showed a decrease in some hippocampal areas. Regarding male animals, stanozolol led to a decrease in neuron number in one hippocampal region. These data allow us to conclude that supra-physiological doses of steroids used in this study, can cause considerable damage to nervous tissue with ultrastructural and consequently behavioral impairment. These changes could interfere with the loss of physical yield and performance of athletes and non-athletes and may cause irreparable damage to individuals making irresponsible use of anabolic steroids.
Resumo As substancias anabólicas tem sido cada vez mais utilizadas por fisiculturistas e atletas com o objetivo de melhorar o desempenho e a estética. No entanto, essa prática tem causado algumas preocupações aos médicos e pesquisadores, devido ao desconhecimento das consequencias que o uso indiscriminado e ilícito dessas substâncias podem causar. Diante disso, este estudo analisou os efeitos de dois esteroides anabolizantes (EA) comercialmente disponíveis, Winstrol Depot® (Stanozolol) e Deposteron® (cipionato de testosterona), na densidade neuronal das regiões corticais límbica, motora e sensitive bem como das áreas CA1, CA2, CA3 do hipocampo. Foram utilizados 60 camundongos Swiss (30 machos e 30 fêmeas), separados em três grupos: controle e dois grupos experimentais, que receberam o EA. De cada cérebro, foram coletadas amostras homotípicas e semi-seriadas em cortes frontais das áreas estabelecidas para o estudo. Os resultados mostraram que as fêmeas tratadas com cipionato de testosterona apresentaram uma redução em todas as regiões analisadas já as fêmeas tratadas com Stanozolol mostraram uma diminuição em algumas áreas do hipocampo. Em relação aos animais machos, o stanozolol levou a uma diminuição na densidade neuronal em uma região do hipocampo. Estes dados nos permitem concluir que doses supra fisiológicas de esteroides utilizadas neste estudo podem causar danos consideráveis ao tecido nervoso com comprometimento ultraestrutural e consequentemente comportamental. Essas alterações podem interferir na perda de rendimento físico e no desempenho de atletas e não atletas e podem causar danos irreparáveis a indivíduos que fazem uso irresponsável destes EA.
Subject(s)
Animals , Male , Female , Rabbits , Anabolic Agents/adverse effects , Stanozolol/adverse effects , Testosterone Congeners , Hippocampus , NeuronsABSTRACT
La función metabólica y de excreción está determinada principalmente por la actividad hepática, esto predispone al hígado a lesión inducida por toxicidad, en donde la disfunción es mediada directa o indirectamente por xenobióticos y/o sus metabolitos. La enfermedad hepática inducida por fármacos (DILI) es una condición poco frecuente, que se relaciona hasta con el 50% de las insuficiencias hepáticas agudas, y de ahí su importancia. La lesión directa puede estar dirigida a hepatocitos, conductos biliares y estructuras vasculares; no obstante, diferentes xenobióticos pueden interferir con el flujo de bilis mediante el bloqueo directo de proteínas de trasporte en los canalículos. Actualmente no existen marcadores absolutos para el diagnóstico de esta entidad y las manifestaciones clínicas pueden ser variables, desde el espectro de alteraciones bioquímicas en ausencia de síntomas, hasta insuficiencia hepática aguda y daño hepático crónico, por lo cual es principalmente un diagnóstico de exclusión basado en evidencia circunstancial. A partir de esta inferencia, se han desarrollado escalas y algoritmos para evaluar la probabilidad de lesión hepática inducida por medicamentos, tóxicos, herbales o suplementos. En la mayoría de los casos, es característico que la condición del paciente mejore cuando se elimina el fármaco responsable del daño. Aunque el patrón colestásico generalmente tiene mejores tasas de supervivencia en comparación con otros patrones, también se asocia con un alto riesgo de desarrollar enfermedad hepática crónica o ser el desencadenante de manifestaciones inmunológicas en el hígado. Se presenta el caso clínico de un paciente con patrón colestásico de DILI por uso de esteroides anabólicos.
Metabolic and excretory function is determined mainly by liver activity which can make this organ susceptible to toxic injury, where dysfunction is directly or indirectly mediated by xenobiotics and/ or their metabolites. Drug-induced liver disease (DILI) is a rare condition, which is associated with up to 50% of acute liver failure, and hence its importance. Direct injury can be directed to hepatocytes, bile ducts, and vascular structures, however, different xenobiotics can interfere with bile flow by directly blocking transport proteins in the canaliculi. Currently there are no definite markers for the diagnosis of this condition, and clinical manifestations can be variable, including biochemical changes in the absence of symptoms to acute liver failure and chronic liver damage, which makes it mainly an exclusion diagnosis based on clinical evidence. Scales and algorithms have been developed to assess the probability of drug, toxic, herbal, or supplement-induced liver injury. In most cases, the patient's condition typically improves when the drug responsible for the injury is removed. Although the cholestatic pattern generally has better survival rates compared to other patterns, it is also associated with a high risk of developing chronic liver disease or acting as a trigger for immune disorders in the liver. The clinical case of a patient with a cholestatic pattern of DILI due to the use of anabolic steroids is presented.
Subject(s)
Humans , Cholestasis , Testosterone Congeners , Chemical and Drug Induced Liver Injury , Liver DiseasesABSTRACT
The steroid hormones are lipids in nature, which play crucial roles in several metabolic and behavioral pathways in mammals. Drug therapy uses sterol hormones for treating some disturbances linked with its deficiency; however, the illicit use of these hormones by amateur and elite athletes to enhance performance or body appearance may lead to several health issues. In this study we evaluated the anxious-like behavior and the long-term memory acquisition of male rats undergoing sedentary life-style or physical effort, with or without anabolic-androgenic steroids (ASC) treatment. The results showed a decrease in anxious-like behavioral levels in rats that received ASC treatment associated or not with physical effort, but this treatment did not affect the acquisition of long-term memory at the dose and experimental model assessed.
Subject(s)
Animals , Rats , Anxiety , Testosterone Congeners/administration & dosage , Rats/abnormalitiesABSTRACT
A adulteração de suplementos alimentares pela adição de substâncias farmacologicamente ativas e um problema que vem se agravando nos últimos anos. Essas substâncias são adicionadas intencionalmente nos produtos, com objetivo de melhorar a sua eficácia, sem que essa adição seja devidamente informada nos rótulos. O consumo de suplementos adicionados de substâncias farmacologicamente ativas nao declaras nos rótulos e, alem de um problema de saúde pública, um risco a carreira de atletas profissionais, quando se trata de doping no esporte. Neste trabalho foram desenvolvidos métodos analíticos baseados em cromatografia líquida para detecção de 19 substâncias farmacologicamente ativas em amostras de suplementos alimentares, nos niveis de contaminação cruzada e adulteração. Para tal, empregou-se a cromatografia líquida de alta eficiência acoplada a detector de arranjo de diodos (HPLC-DAD) e a cromatografia líquida acoplada a espectrometria de massas sequencial (LC-MS/MS). As substâncias investigadas apresentam ação androgênica e anabólica (i.e. testosterona, metiltestostetona, propionato de testosterona, decanoato de testosterona, trembolona, estanozolol, dehidroepiandrosterona, androstenediona, decanoato de nandrolona, oxandrolona e metasterona), estimulante (i.e. cafeína), anorexigena (i.e. sibutramina), diurética (i.e. amilorida, bumetanida, furosemida, hidroclorotiazida e clortalidona) e laxante (i.e. fenolftaleina). Entre os métodos de preparo de amostra avaliados (Quechers e extração sólido-líquido seguida de uma etapa de precipitação de proteína), a extração sólido-líquido empregando metanol como solvente extrator e ZnSO4 como agente precipitante apresentou-recuperação acima de 80% para todas as substâncias avaliadas, sendo selecionado para o fim deste estudo. Os métodos analíticos propostos apresentaram limites de detecção e de quantificação na faixa de contaminação, foram seletivos e lineares com r2 superior a 0,99 na faixa de concentração de interesse para todas as substâncias e valores de recuperação, precisão e exatidão dentro dos valores aceitáveis. Um conjunto amostral representativo dos suplementos alimentares comercializados no Brasil, constituído por 230 amostras, foi analisado sendo que mais de 25% do conjunto amostra foram positivos para cafeína (48), sibutramina (14), fenolftaleína (2) e furosemida (3), isoladas ou associadas entre si. Os métodos desenvolvidos utilizaram um preparo de amostra simples e apresentaram resultados satisfatórios para a investigação de possível adulteração ou contaminação com 19 das substâncias de interesse. Dos 58 suplementos alimentares adulterados, apenas 11 podem ser considerados adulterados por contaminação cruzada. Os demais, são consideradas adições dolosas por parte dos fabricantes com objetivo de melhorar a eficiência dos seus produtos. Os resultados aqui apresentados indicam a necessidade de ações mais efetivas por parte das autoridades sanitárias no sentido de fiscalizar com mais eficiência a produção e a comercialização desses produtos e alertar a população para que fiquem atentos a possível adulteração de suplementos alimentares e aos riscos associados ao consumo desses produtos
The adulteration of dietary supplements by the addition of pharmacologically active substances is a serious issue, which is aggravating steadily. These substances are added intentionally in various products, with the aim of improving their effectiveness, but without proper labeling stating so. In addition to a public health problem, the consumption ofsupplements added with undeclared pharmacologically active substances also represents a career risk for professional athletes when it comes to doping in sport. In the present work, analytical methods based on liquid chromatography were developed for the detection of 19 pharmacologically active substances in dietary supplement samples at the levels of crosscontamination and adulteration. For this purpose, high performance liquid chromatography/diode array detector (HPLC-DAD) and liquid chromatography/tandem mass spectrometry (LC-MS/MS) were used. The investigated substances comprise of androgenic and anabolic effects (ie testosterone, testosterone propionate, testosterone decanoate, trenbolone, stanozolol, dehydroepiandrosterone, androstenedione, nandrolone decanoate, oxandrolone and metasterone), stimulant (ie caffeine), anorexigenic (ie sibutramine), diuretic (ie amiloride, bumetanide, furosemide, hydrochlorothiazide and chlorthalidone) and laxative (ie phenolphthalein). Among the sample preparation methods evaluated (Quechers and solidliquid extraction followed by a protein precipitation step), solid-liquid extraction using methanol as extraction solvent and ZnSO4 as the precipitating agent has been chosen as it has shown recovery values above 80% for all evaluated substances. The proposed analytical methods had limits of detection and quantification within the contamination range, they were also selective and linear showing r2 values higher than 0.99 in the concentration range of interest for all substances and accuracy within acceptable values. A representative sampling of dietary supplements marketed in Brazil, consisting of 230 samples, was analyzed and more than 25% have shown to be positive for caffeine (48), sibutramine (14), phenolphthalein (2) and furosemide (3), isolated or associated with each other. The methods developed used a simple sample preparation and presented satisfactory results for the investigation of possible adulteration or cross-contamination for the 19 of the substances of interest. From a total of 58 adulterated dietary supplements, only 11 could be considered adulterated by crosscontamination. The remaining are considered to be intentional additions by manufacturers in order to improve the efficiency of their products. The results presented in this study indicate the need for more effective measures by the health authorities towards the production and marketing of these products so that the general public is aware of their potential adulteration and the risks associated with their consumption
Subject(s)
Mass Spectrometry/instrumentation , Drug Contamination/prevention & control , Chromatography, Liquid/instrumentation , Dietary Supplements/analysis , Caffeine , Testosterone Congeners/adverse effects , Diuretics/adverse effectsABSTRACT
Androgen therapy has proven efficacy in treating patients with bone marrow failure who are not candidates for bone marrow transplantation. Herein, we report on a case of colonic angioectasia secondary to oxymetholone use in an adolescent patient with Hoyeraal-Hreidarsson syndrome (HHS). A 13-year-old Caucasian male with HHS characterized by cerebellar hypoplasia, developmental delay, microcephaly, esophageal strictures and myelodysplasia presented with severe hematochezia from colonic angioectasia secondary to long-term oxymetholone therapy. These vascular lesions resolved spontaneously once this anabolic steroid was discontinued. While androgen therapy is often recommended for certain anemias and myelodysplastic syndromes, clinicians should be aware of the potential complication in developing these perceived uncommon colonic angioectasias. Moreover, pediatric gastroenterologists should familiarize themselves in identifying these vascular lesions by colonoscopy, especially among the high risk groups on long-term anabolic steroid therapy.
Subject(s)
Adolescent , Humans , Male , Anemia , Bone Marrow , Bone Marrow Transplantation , Colon , Colonoscopy , Constriction, Pathologic , Gastrointestinal Hemorrhage , Microcephaly , Myelodysplastic Syndromes , Oxymetholone , Testosterone CongenersABSTRACT
Los esteroides anabólicos típicamente usados por jóvenes, atletas y culturistas para incrementar el musculo y la fuerza son peligrosos, están accesibles, y se prescriben de manera errónea como eficaces, pero con riesgo bajo. No solo los atletas consumen esteroides anabólicos. Algunos jóvenes los toman para lucir más musculosos o para quemar grasa. El objetivo del estudio fue identificar los factores asociados al uso de anabólicos esteroides en jóvenes de 16 a 25 años que asisten al Gimnasio Fitness Family Caff de Asunción, conocer los datos socio-demográficos, caracterizar los conocimientos y el uso de esteroides anabólicos en el gimnasio y determinar el factor de consumo de esteroides anabólicos de acuerdo a la práctica en el gimnasio. Estudio tipo observacional descriptivo de corte transversal que contó con la participación de 41 jóvenes provenientes en su mayoría de Asunción. En cuanto a los factores se determinó que su uso está motivado por mejorar el aspecto físico, es decir, por un factor estético al igual que por la participación en competencias fitness
Anabolic steroids, typically used by young people, athletes and bodybuilders to increase muscle and strength, are dangerous, accessible and are prescribed incorrectly as effective, but with low risk. Not only athletes consume anabolic steroids. Some young people take them to look more muscular or for fat burning. The study had the following objectives: To identify factors associated with the use of anabolic steroids in 16 to 25 years young people who attend the Family Fitness Caff Gym in Asuncion, to know the socio-demographic data, characterize the knowledge and use of anabolic steroids in the gym, and determine the consumption factor of anabolic steroids according to the practice in the gym. This was an observational descriptive cross-sectional study. The study had the participation of 41 young people, mostly from Asuncion. In relation to the factors, it was determined that their use was motivated to improve their physical appearance; this is to say, for an aesthetic factor as well as for the participation in fitness competitions.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Physical Endurance/drug effects , Beauty , Testosterone Congeners/administration & dosage , Paraguay , Cross-Sectional Studies , Testosterone Congeners/adverse effects , Off-Label UseABSTRACT
Os esteroides anabolizantes têm sido usados como arma terapêutica em diversas condições clínicas. Entretanto, o uso abusivo e indiscriminado, associado a outros suplementos nutricionais, tem gerado efeitos adversos graves. Relato do caso: Sexo masculino, 21 anos, admitido com náuseas, astenia, hiporexia, cefaleia e hipertensão arterial. Exames no sangue evidenciaram Cr: 3,9 mg/dl U:100 mg/dl e Cálcio total 14 mg/dl. Ultrassonografia e biópsia renal compatíveis com nefrocalcinose. Houve melhora gradativa da função renal e da calcemia após hidratação vigorosa e furosemida. Entretanto, após 1 ano, persistiram depósitos renais de cálcio e relação córticomedular reduzida ao ultrassom e creatinina estável em 1,4 mg/dl. Casos anteriores evidenciaram necrose tubular aguda e nefrite intersticial com poucos depósitos de cálcio no interstício renal. Nesse caso, encontramos nefrocalcinose acentuada associada à nefroesclerose. O objetivo deste estudo é relatar a ocorrência de injúria renal aguda com nefrocalcinose associada ao uso de esteroide anabolizante e oferecer uma revisão do assunto. .
The anabolic steroid have been used as a therapeutic tool in various clinical conditions. However, indiscriminate use associated with other nutritional supplements has generated serious adverse effects. Case report: Male, 21 years old, admitted with nausea, fatigue, appetite loss, headache and hypertension. Blood tests showed Cr: 3.9 mg% U: 100 mg% and Total Calcium 14 mg/dl. Ultrasonography and renal biopsy were consistent with nephrocalcinosis. There has been gradual improvement in renal function and calcium levels after vigorous hydration and furosemide. However, after 1 year, renal calcium deposits persist, corticomedullary ratio reduced in ultrasound and stable creatinine of 1.4 mg/dl. Previous cases showed acute tubular necrosis and interstitial nephritis with little calcium deposits in the renal interstitium. In this case we found severe nephrocalcinosis associated with nephrosclerosis. Our objective is to report the occurrence of acute kidney Injury with nephrocalcinosis associated with use of anabolic steroid and provide a review of the matter. .
Subject(s)
Humans , Male , Young Adult , Nephrocalcinosis/chemically induced , Testosterone Congeners/adverse effectsABSTRACT
BACKGROUND: Knowing the potential for and limitations of information generated using different evaluation instruments favors the development of more accurate functional diagnoses and therapeutic decision-making. OBJECTIVE: To investigate the relationship between the number of compensatory movements when climbing up and going down stairs, age, functional classification and time taken to perform a tested activity (TA) of going up and down stairs in boys with Duchenne muscular dystrophy (DMD). METHOD: A bank of movies featuring 30 boys with DMD performing functional activities was evaluated. Compensatory movements were assessed using the climbing up and going down stairs domain of the Functional Evaluation Scale for Duchenne Muscular Dystrophy (FES-DMD); age in years; functional classification using the Vignos Scale (VS), and TA using a timer. Statistical analyses were performed using the Spearman correlation test. RESULTS: There is a moderate relationship between the climbing up stairs domain of the FES-DMD and age (r=0.53, p=0.004) and strong relationships with VS (r=0.72, p=0.001) and TA for this task (r=0.83, p<0.001). There were weak relationships between the going down stairs domain of the FES-DMD-going down stairs with age (r=0.40, p=0.032), VS (r=0.65, p=0.002) and TA for this task (r=0.40, p=0.034). CONCLUSION: These findings indicate that the evaluation of compensatory movements used when climbing up stairs can provide more relevant information about the evolution of the disease, although the activity of going down stairs should be investigated, with the aim of enriching guidance and strengthening accident prevention. Data from the FES-DMD, age, VS and TA can be used in a complementary way to formulate functional diagnoses. Longitudinal studies and with broader age groups may supplement this information. .
CONTEXTUALIZAÇÃO: Conhecer as potencialidades e limitações das informações geradas por diferentes instrumentos de avaliação favorece o desenvolvimento mais preciso do diagnóstico funcional e da tomada de decisão terapêutica. OBJETIVO : Investigar a relação entre o número de movimentos compensatórios ao subir e descer escadas, idade, classificação funcional e tempo de realização de atividade (TA) em meninos com Distrofia Muscular de Duchenne (DMD). MÉTODO : Foi utilizado banco de filmes de 30 meninos com DMD realizando atividades funcionais. Os movimentos compensatórios foram avaliados pela Escala de Avaliação Funcional para Distrofia Muscular de Duchenne (FES-DMD), domínio subir e descer escada; a idade, mensurada em anos; a classificação funcional foi pesquisada pela Escala de Vignos (EV), e o TA foi cronometrado. Foi utilizado o teste de correlação de Spearman. RESULTADOS : Existe moderada relação entre a FES-DMD-subir escada e a idade (r=0,53, p=0,004) e forte relação com a EV (r=0,72, p=0,001) e TA dessa tarefa (r=0,83, p<0,001). Houve fraca relação entre a FES-DMD-descer escada e a idade (r=0,40, p=0,032), EV (r=0,65, p=0,002) e o TA dessa tarefa (r=0,40, p=0,034). CONCLUSÃO : Esses achados indicam que a avaliação da tarefa de subir escada pode trazer informações mais relevantes sobre a evolução da doença, embora a atividade de descer escada deva ser pesquisada visando à orientação e prevenção de acidentes. A utilização conjunta de dados provenientes da FES-DMD, da idade e do TA pode se complementar para formulação do diagnóstico funcional. Estudos longitudinais e com outras faixas etárias mais amplas podem complementar tal informação. .
Subject(s)
Humans , Male , Prostatic Hyperplasia/metabolism , Receptors, Androgen/metabolism , Binding, Competitive , Buffers , Charcoal , Cytosol/metabolism , Dextrans , Dihydrotestosterone/metabolism , Electrophoresis, Agar Gel , Enzyme Activation/drug effects , Estrenes/metabolism , Metribolone , Molybdenum/pharmacology , Progesterone/metabolism , Protease Inhibitors/pharmacology , Temperature , Tartrates/pharmacology , Testosterone Congeners/metabolismABSTRACT
O objetivo da presente revisão sistemática foi traçar a prevalência, as formas de indicação e os efeitos adversos dos suplementos alimentares (SA) e esteroides anabólicos androgênicos (EAA), cujo uso é relatado por praticantes de musculação nas academias de ginástica do Brasil. Para desenvolvimento deste estudo foi realizada, em novembro de 2011, uma busca nas bases de dados Medline, Scielo, Bireme e Lilacs utilizando as palavras-chave: esteroides anabólicos androgênicos, suplementos nutricionais e academias de ginástica. Para ser incluído, o estudo deveria ter investigado o uso de recursos ergogênicos em academias do Brasil. De acordo com os critérios de inclusão, foram selecionadas em um primeiro momento 93 investigações, mas apenas 18 foram incluídas. Os estudos selecionados demonstraram que as regiões Sul e Sudeste são as que possuem maior número de estudos. A maior prevalência de consumo dos SA foi em Belo Horizonte (90,8%), seguido por Vitória (70%), Cascavel (66%) e Curitiba (50,61%), e os produtos mais consumidos foram: proteínas, aminoácidos e creatinas. Para os EAA, a maior prevalência encontrada foi em Belo Horizonte com 85%, seguido por Aracaju (31%) e Rio Grande do Sul (24,9%). Os produtos mais utilizados foram o Decanoato de Nandrolona, a Testosterona e o Estanozolol. Os efeitos colaterais predominantes dos EAA foram surgimento de acne (46 a 94%) e agressividade (47 a 73%). Tanto o consumo de SA quanto o uso dos esteroides anabólicos androgênicos encontram-se exacerbados nas academias brasileiras, principalmente, na região Sudeste. Além disso, o uso abusivo dos EAA ocorre devido à falta de informações sobre suas contra indicações, repercutindo em inúmeros efeitos adversos à saúde.
Objective: The objective of the present study was to systematically review the prevalence, indicative ways, and adverse effects of ergogenic resources, such as dietary supplements (DS) and anabolic androgenic steroids (AAS), that were reported, by bodybuilders in gyms in Brazil. Methods: References search was performed in November 2011 in the Medline, SciELO, BIREME, and Lilacs data basis by the key-words: anabolic-androgenic steroids, nutritional supplements, and gyms. To be included the studies should have investigated the prevalence of the use of ergogenic resources in gyms in Brazil. Ninety-three investigations were selected, but only 18 were included. Results: The highest prevalence of DS consumption was in Belo Horizonte (90.8%), followed by Vitoria (70%), Cascavel (66%) and Curitiba (50.61%). For the AAS use, the highest prevalence was in Belo Horizonte with 85%, followed by Aracaju (31%) and Rio Grande do Sul (24.9%). The products mainly consumed as DS were: derived proteins, amino acids and creatine. The most widely used AAS increase were Deca-Durabolin, Sustanon and Winstrol. Side effects mostly observed by the AAS users were the appearance of acne (46 to 94%) and aggressiveness (47 to 73%). Conclusion: Both the use of DS and AAS are exacerbated in the gyms of Brazil, mainly in the Southeast. In addition, the abuse of AAS is due to a lack of information about their contraindications, resulting in innumerous adverse health effects.
Subject(s)
Humans , Dietary Supplements , Fitness Centers , Testosterone CongenersABSTRACT
PURPOSE: To evaluate the actual impact of testosterone replacement therapy (TRT) on patients with lower urinary tract symptom (LUTS), without benign prostate hyperplasia (BPH) medication. MATERIALS AND METHODS: Two hundreds forty-six patients underwent TRT using intramuscular injection of 3 months bases injection of testosterone 100 mg undecanoate over a year. Among them, 17 patients had moderate LUTS with a maximal flow rate of at least 10 ml/s but did not take any BPH-specific medication during TRT. The changes in prostate specific antigen (PSA), International Prostate Symptom Score (IPSS), and uroflowmetery were measured before and after TRT. RESULTS: After TRT, PSA remained unchanged after a year of treatment (p=0.078). Compared with their counterparts (n=229), the patients without BPH medication had similar baseline prostate characteristics in all variables, including prostate volume, IPSS, maximal flow rate, voiding volume, and PSA, except the median amount of residual urine, which was higher in the patients without BPH medication (21 ml vs. 10 ml). In the no-BPH medication group, the total IPSS score was decreased significantly (p=0.028), both in storage symptoms (questionnaire 2, 4, 7) and voiding symptoms (questionnaire 1, 3, 5, 6), while the maximal flow rate and residual urine amount remained unchanged after a year of TRT. During the median follow up of 15.1 months, no patients experienced urinary retention, BPH-related surgery, or admission for urinary tract infection. CONCLUSIONS: Over a year of TRT for the no-BPH medication patients with moderate LUTS and maintained a relatively high maximal flow rate and improved both storage and voiding symptoms, without the clinical progression of BPH or rising PSA.
Subject(s)
Humans , Follow-Up Studies , Hyperplasia , Injections, Intramuscular , Lower Urinary Tract Symptoms , Prostate , Prostate-Specific Antigen , Prostatic Hyperplasia , Testosterone , Testosterone Congeners , Urinary Retention , Urinary TractABSTRACT
Brachyhypopomus draco, new species, is described from central, southern and coastal regions of Rio Grande do Sul state, Brazil, and Uruguay. It is diagnosed from congeners by, among other characters, the shape of the distal portion of the caudal filament in mature males, which during the reproductive period forms a distinct paddle shape structure.
Brachyhypopomus draco, espécie nova, é descrita para as regiões central, sul e costeira do estado do Rio Grande do Sul, Brasil, e Uruguai. Ela é diagnosticada de seus congêneres, entre outros caracteres, pela porção final do filamento caudal de machos maduros, que adquire a forma de um remo durante o período reprodutivo.
Subject(s)
Animals , Biodiversity , Testosterone Congeners/physiology , Gymnotiformes/classification , Sex CharacteristicsABSTRACT
Testosterone (T) as a compound for treatment of T deficiency has been available for almost 70 years, but the pharmaceutical formulations have been less than ideal. Traditionally, injectable T esters have been used for treatment, but they generate supranormal T levels shortly after the 2-3 weekly injection interval. T levels then decline very rapidly, becoming subnormal during the days preceding the next injection. The rapid fluctuations in plasma T are subjectively experienced as disagreeable. T undecanoate (TU) is a new injectable T preparation with a considerably better pharmacokinetic profile. After two initial injections separated by a 6-week interval, the following intervals between two injections are generally 12 weeks, eventually amounting to a total of four injections per year. Plasma T levels with this preparation are nearly always in the range of normal men, as are its metabolic products estradiol and dihydrotestosterone (DHT). It reverses the effects of hypogonadism on bone and muscle and metabolic parameters, and on sex functions. It is suitable for male contraception. Its safety profile is excellent because of the continuous normalcy of plasma T levels. No polycythemia has been observed and no adverse effects on lipid profiles. Prostate safety parameters are well within reference limits. TU is a valuable treatment option of androgen deficiency.
Subject(s)
Humans , Male , Contraceptive Agents, Male , Pharmacokinetics , Therapeutic Uses , Erectile Dysfunction , Drug Therapy , Hypogonadism , Drug Therapy , Injections, Intramuscular , Testosterone , Blood , Pharmacokinetics , Therapeutic Uses , Testosterone Congeners , Pharmacokinetics , Therapeutic UsesABSTRACT
Se analizan los motivos por los cuales el doping no encaja en la estructura del deporte, es potencialmente peligroso para la salud y se deben precisar conceptos. La clasificación farmacológica de las sustancias que no se deben usar en el deporte incluyen: hormonas peptídicas y derivados, hormonas esteroides anabólicas, estimulantes del sistema nervioso central, analgésicos, narcóticos (opioides), betabloqueadores, diuréticos, sustancias sujetas a ciertas restricciones y métodos de doping. Asimismo, se consideran los diversos efectos farmacodinámicos y farmacopatológicos, como también varios tipos de acciones disuasivas: preventivas, controladoras y sancionadoras.
The reasons why doping does not fit into the structure of sport, it is potentially dangerous for health and concepts must be specified are analyzed. The pharmacological classification of substances not to be used in sport include: peptide hormones and derivatives, anabolic steroid hormones, central nervous system stimulants, pain relievers, narcotics (opioids), beta-blockers, diuretics, substances subject to certain restrictions and methods of doping. Likewise, the various pharmacodynamic and pharmacopathological effects are considered, as well as various types of dissuasive actions: preventive, controlling and sanctioning.
Subject(s)
Humans , Male , Female , Sports , Pharmaceutical Preparations , Testosterone Congeners , Doping in Sports , Primary Prevention , Central Nervous System StimulantsABSTRACT
Androgens control a broad range of physiological functions. The androgen receptor (AR), a steroid receptor that mediates the diverse biological actions of androgens, is a ligand inducible transcription factor. Abnormalities in the androgen signaling system result in many disturbances ranging from changes in gender determination and sexual development to psychiatric and emotional disorders. Androgen replacement therapy can improve many clinical conditions including hypogonadism and osteoporosis, but is limited by the lack of efficacious and safe therapeutic agents with easy delivery options. Recent progress in the area of gene regulation by steroid receptors and by selective receptor modulators provides an opportunity to examine if selective androgen receptor modulators (SARMs) could address some of the problems associated with current androgen therapy. Since the composition of the transcriptional initiation complex recruited by liganded AR determines the specificity of gene regulation, synthetic ligands aimed at initiating transcription of tissue and promoter specific genes offers hope for developing better androgen therapy. Establishment of assays that predict synthetic ligand activity is critical for SARM development. Advancement in high throughput compound screening and gene fingerprinting technologies, such as microarrays and proteomics, will facilitate and accelerate identification of effective SARMs.
Subject(s)
Humans , Male , Androgen Antagonists , Pharmacology , Androgen Receptor Antagonists , Androgens , Chemistry , Metabolism , Chlormadinone Acetate , Pharmacology , Receptors, Androgen , Physiology , Receptors, Cytoplasmic and Nuclear , Physiology , Testosterone Congeners , PharmacologyABSTRACT
Andropausa é uma designaçäo inapropriada para o quadro clínico resultante do declínio progressivo da produçäo androgênica encontrado em pelo menos 20 por cento dos homens com idad entre 60 e 70 anos, e que algumas vezes se inicia a partir dos 50 anos. Uma designaçäo mais adequada é insuficiência androgênica parcial do homem idoso. Como a produçäo de testosterona diminui regularmente, em homens de 75 anos os níveis médios de testosterona säo somente 65 por cento daqueles dos adultos jovens, sendo que pelo menos 25 por cento destes idosos apresentam níveis subnormais de testosterona biodisponível. A etiologia deste declínio da testosterona dependente da idade é multifatorial e envolve alteraçöes testiculares primárias, disfunçäo da regulaçäo neuroendócrina das gonadodropinas, elevaçäo das concentraçöes séricas de globulina ligadora de hormônios sexuais e reduçäo da sensibilidade dos receptores androgênicos. A senescência é acompanhada de uma série de sinais e sintomas, muitos deles baastante semelhantes aos observados em hipogonádicos jovens. Este quadro clínico complexo pode se dever aos efeitos conjuntos do próprio processo de senescência e de doeças intercorrentes. No entanto, existem evidências que o declínio dos níveis de testosterona próprio da idade é, pelo menos em parte, codeterminante deste quadro clínico, visto que a reposiçäo androgênica tem mostrado efeitos favoráveis em mais de 30 por cento destes idosos sintomáticos. No momento, esta reposiçäo hormonal deveria somente ser considerada em presença de níveis séricos de testosterona abaixo dos limites normais mínimos para adultos jovens, acompanhada de sinais inequívocos de insuficiência androgênica, na ausência de outras causas reversíveis de hipoandrogenismo e após a exclusäo de contra-indicaçöes.
Subject(s)
Humans , Male , Middle Aged , Aging/physiology , Testosterone Congeners/therapeutic use , Testosterone/deficiency , Risk Factors , Hormone Replacement Therapy , Hormone Replacement Therapy/adverse effects , Hormone Replacement Therapy/methods , Testosterone/bloodABSTRACT
Changes in iron status and bone marrow Junctions are frequently observed in the elderly. These phenomena are often associated with chronic diseases and/or neoplcfsmas. In a minority of elderly subjects; it is not possible to identify the causes of anemia. This study was carried out to clarify the functional capacity of the erthropoietic tissues of the aged rats, to investigate the role of IL-6 in erthropoietic activity, and to evaluate the short-term testosterone therapy. Thirty healthy male Sprague-Dawley rats were divided according to their age into group I [16-week-old; n = 6], group II [48-week-old; n=12], group III [72-week-old; n=I2]. Six rats enrolled in each elderly group [groups II and III] received s.c. testosterone propionate; 2 mg/100 g body weight every other day for 10 days [Groups lIb and Illb]. The remaining rats not received testesterone were named groups [Ila and IlIa]. One day after the last injection, bone marrow aspirates were performed to evaluate the erthropoietic activity and iron stores in the erythroid precursors. In addition, a peripheral haemogram and determination of serum levels of iron, TIBC, IL-6, and free testosterone were done. Significant age-linked changes were observed in the form of decreased serum levels of free testosterone, IL-6, TIBC, RBCs count, and Hb levels as well as an increase in serum iron level in groups Ila and IIla. Bone marrow hypocellularity with a decrease in the amount of iron storage were especially remarkable in Group IlIa. Moreover improvement in the function of erythropoietic tissues in Group lib indicated by erythroid hyperplasia and an increase in the amounts of iron storage. However, reduced serum IL-6 was not affected by testosterone therapy. These data reveal that senile anemias are of hypoproliferaitue character. Testosterone and IL-6 may be, at least in part, the important factors in determining an age-associated decrease in erythropoiesis
Subject(s)
Male , Animals, Laboratory , Testosterone Congeners/adverse effects , Interleukin-6 , Erythropoiesis , Aged , Rats , Testosterone , Bone Marrow/analysis , HistologyABSTRACT
Se comparan las respuestas terapéuticas en pacientes con diagnóstico de Síndrome de Sjögren que padecen de queratoconjuntivitis seca resistentes a los tratamientos tradicionales de lágrimas artificiales, lentes y otros, en dos grupos de pacientes de 18 y 32 casos con tratamientos de gammaglobulina humana: intacglobín (100 mg por kilo de peso cada 15 días por vía subcutánea interescapular por 3 meses) y andrógenos de depósito (100 mg cada 15 días por vía im durante 3 meses). Se evaluaron los niveles de inmunoglobulinas IgG, IgA, IgM e IgE, recuento de células sanguíneas factor reumatoideo, proteína C reactiva y estudio microbiológico. Ambas terapéuticas muestran una mejoría estadísticamente significativa p < 0,001 en los resultados obtenidos en la prueba de Shirmer I y en la negativización de las lesiones corneales valoradas en lámpara de hendidura después de tinción con fluorescencia. Se plantea las ventajas del uso de gammaglobulinas a causa de las contraindicaciones en el uso de andrógenos